缬沙坦联合瑞舒伐他汀治疗高血压合并冠心病患者的临床效果及其对血脂的影响

Clinical Effect of Valsartan Combined with Rosuvastatin in the Treatment of Hypertensive Patients with Coronary Heart Disease and Its Influence on Blood Lipid

目的分析缬沙坦联合瑞舒伐他汀治疗高血压(Hypertension,HTN)合并冠状动脉粥样硬化性心脏病(Coronary Heart Disease,CHD)的疗效。方法选取2021年1月—2023年6月睢宁县中医院收治的66例HTN合并CHD患者为研究对象,按随机数表法分成两组,每组33例。对照组采用瑞舒伐他汀治疗,观察组采用缬沙坦联合瑞舒伐他汀治疗。对比两组疗效、收缩压、舒张压、血清血脂表达水平和生活质量评分。结果观察组疗效优于对照组,差异有统计学意义(P<0.05)。治疗后观察组清晨血压较对照组更低,差异有统计学意义(P<0.05)。治疗后两组患者血清胆固醇、三酰甘油、低密度脂蛋白胆固醇均降低,且观察组的三酰甘油、胆固醇、低密度脂蛋白胆固醇[(1.19±0.15)、(2.63±0.51)、(2.18±0.55)mmol/L]较对照组更低,差异有统计学意义(P均<0.05);治疗后观察组的高密度脂蛋白胆固醇高于对照组,差异有统计学意义(P<0.05)。治疗后观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论缬沙坦联合瑞舒伐他汀治疗HTN合并CHD的临床疗效好,可有效控制患者血压、血脂水平,有利于提高生活质量。

Objective To analyze the efficacy of valsartan combined with rosuvastatin in the treatment of hypertension(HTN)combined with coronary heart disease(CHD).Methods Totally 66 patients diagnosed of HTN with CHD admitted to Suining County Hospital of Traditional Chinese Medicine from January 2021 to June 2023 were selected as the study objects and were divided into two groups according to random number table method,with 33 cases in each group.The single rosuvastatin was used the control group,and the observation group was treated with while valsartan and rosuvastatin were used to treat the observation group.The therapeutic effect,systolic blood pressure,diastolic blood pressure,serum lipid expression level and quality of life score were compared between the two groups.Results The curative effect of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the morning blood pressure in the observation group was lower than the control group,and the difference was statistically significant(P<0.05).After treatment,serum cholesterol,triglyceride and low density lipoprotein cholesterol in both groups were decreased,and the triglyceride,triglyceride and low density lipoprotein cholesterol in observation group[(1.19±0.15),(2.63±0.51)and(2.18±0.55)mmol/L]after treatment,lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,serum high density lipoprotein cholesterol in the observation group was higher than that of the control group,and the differences were statistically significant(P<0.05).After treatment,the life quality score of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).Conclusion Valsartan combined with rosuvastatin has good clinical efficacy in the treatment of HTN combined with CHD,which can effectively control the blood pressure and lipid levels of patients,and is conducive to improving the quality of life.